ROSEVILLE, Minn., April 21,
2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq:
CLXT), a plant-based synthetic biology company, will host a
conference call and webcast on Thursday, May
5, 2022, at 4:30 p.m. Eastern
Time to discuss results for the first quarter ended
March 31, 2022. A press release
detailing these results will be issued prior to the call.
President and Chief Executive Officer, Michael A. Carr, and Chief Financial Officer,
Bill Koschak, will host the
conference call, followed by a question-and-answer session. The
conference call will be accompanied by a presentation, which can be
viewed during the webcast or accessed via the investor relations
section of the Company's website here.
To access the call, please use the following information:
Date: Time: Toll Free
dial-in number: Toll/International dial-in
number: Conference
ID:
|
Thursday, May 5,
2022 4:30 p.m. EST, 1:30 p.m.
PST
+1 888-317-6003
+1 412-317-6061
2452642
|
Participants should call the conference telephone number 5 to 10
minutes prior to the start time. An operator will register each
participant's name and organization. The conference call will also
be broadcast live and available for replay via the investor
relations section of the Company's website here.
A replay of the webcast will be available for 30 days following
the event.
Toll Free Replay
Number: International Replay
Number:
Replay ID:
|
+1
877-344-7529 +1
412-317-0088 9265408
|
About Calyxt:
Calyxt (Nasdaq: CLXT) is a plant-based synthetic biology
company. The Company leverages its proprietary PlantSpring™
technology platform to engineer plant metabolism to produce
innovative high value plant-based chemistries for use in customers'
materials and products. As plant-based solutions, the Company's
synthetic biology products can be used in helping customers meet
their sustainability targets and financial goals. Calyxt's
diversified offerings are primarily delivered through its
proprietary BioFactory™ production system. For more information,
visit www.calyxt.com.
PlantSpring, BioFactory, Plant Cell Matrix™, and the Calyxt logo
are trademarks of Calyxt, Inc. Any other trademarks belong to their
respective owners.
Forward-Looking Statements
This communication contains "forward-looking statements" within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. In some cases, you can
identify these statements by forward-looking words such as
"anticipates," "believes," "continue," "estimates," "expects,"
"intends," "may," "might," "plans," "predicts," "projects,"
"should," "targets," "will," or the negative of these terms and
other similar terminology. Forward-looking statements in this press
release include statements about the Company's future financial
performance, including its cash runway; its product pipeline and
development; its business model and strategies for the development,
commercialization and sales of commercial products; commercial
demand for its synthetic biology solutions; the development and
deployment of its PlantSpring technology platform; its ability to
deploy and leverage its artificial intelligence and machine
learning (AIML) capabilities; the ability to scale production
capability for its BioFactory production system; potential
development agreements, partnerships, customer relationships, and
licensing arrangements and their contribution to its financial
results, cash usage, and growth strategies; the potential impact of
the COVID-19 pandemic on its business and operating results; and
anticipated trends in its business. These and other forward-looking
statements are predictions and projections about future events and
trends based on the Company's current expectations, objectives, and
intentions and are premised on current assumptions. The Company's
actual results, level of activity, performance, or achievements
could be materially different than those expressed, implied, or
anticipated by forward-looking statements due to a variety of
factors, including, but not limited to: the impact of increased
competition, including competition from a broader array of
synthetic biology companies; competition for customers, partners,
and licensees and the successful execution of development and
licensing agreements; disruptions at its key facilities, including
disruptions impacting its BioFactory production system; flaws in
AIML algorithms, insufficiency of data inputs required by such
algorithms, and human error in interacting with AIML; changes in
customer preferences and market acceptance of its products; changes
in market consensus as to what attributes are required for a
product to be considered "sustainable"; the impact of adverse
events during development, including unsuccessful pilot production
of plant-based chemistries or field trials; the impact of improper
handling of its product candidates during development; failures by
third-party contractors; inaccurate demand forecasting or milestone
and royalty payment projections; the effectiveness of
commercialization efforts by commercial partners or licensees;
disruptions to supply chains, including raw material inputs for its
BioFactory; the impact of changes or increases in oversight and
regulation; disputes or challenges regarding intellectual property;
proliferation and continuous evolution of new technologies;
management changes; dislocations in the capital markets; the
severity and duration of the evolving COVID-19 pandemic and the
resulting impact on macro-economic conditions; and other important
factors discussed under the caption entitled "Risk Factors" in the
Company's Annual Report on Form 10-K. Any forward-looking
statements made by management of the Company are based only on
currently available information and speak only as of the date of
this report. Except as otherwise required by securities and other
applicable laws, the Company does not assume any obligation to
publicly provide revisions or updates to any forward-looking
statements, whether as a result of new information, future
developments or otherwise, should circumstances change, except as
otherwise required by law.
Contacts:
|
|
|
|
|
|
Calyxt Media
Contact:
|
Calyxt Investor
Relations Contact:
|
|
David Rosen/ John
Garabo/ Michael Barron
Argot
Partners
(212)
600-1902
media@calyxt.com
|
Kimberly Minarovich/
Cameron Willis
Argot
Partners
(212)
600-1902
investors@calyxt.com
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calyxt-to-host-first-quarter-2022-financial-results-conference-call-and-webcast-on-thursday-may-5-2022-at-430-pm-eastern-time-301530052.html
SOURCE Calyxt, Inc.